Michael Mikhail
Medical Oncology · Malvern, PANPI 1043384035
Payments from drug & device makers
Across 124 payments — averaging $29.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$479
- Pharmacyclics LLC, An Abbvie Company$410
- Sanofi$367
- AstraZeneca$324
- Bristol Myers Squibb$246
- Caris MPI, Inc.$180
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,34693%
- Education$2707%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 17 | $479 |
| Pharmacyclics LLC, An Abbvie Company | 12 | $410 |
| Sanofi | 4 | $367 |
| AstraZeneca | 14 | $324 |
| Bristol Myers Squibb | 11 | $246 |
| Caris MPI, Inc. | 3 | $180 |
| Servier Pharmaceuticals LLC | 4 | $159 |
| Seagen Inc. | 2 | $138 |
| Akcea Therapeutics, Inc. | 2 | $132 |
| GSK | 1 | $125 |
| Johnson & Johnson | 5 | $119 |
| Genentech USA, Inc. | 6 | $102 |
| Merck | 5 | $67 |
| Gilead(2 entities) | 4 | $62 |
| Adaptive Biotechnologies Corporation | 2 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Novartis | 3 | $51 |
| Amgen | 3 | $49 |
| Daiichi Sankyo Inc. | 1 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $41 |
| Eisai Inc. | 2 | $36 |
| EMD Serono, Inc. | 1 | $32 |
| Stemline Therapeutics Inc. | 2 | $32 |
| Dendreon Pharmaceuticals LLC | 1 | $32 |
| Tesaro, Inc. | 1 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
| Pfizer | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 2 | $25 |
| Verastem, Inc. | 1 | $22 |
| Mylan Institutional Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $13 |
| Aurobindo Pharma USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,617 in reported general payments places this provider in the 35th percentile of 238 medical oncology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 11 | $57,661 |
| Anastrozole | 16 | $1,013 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Malvern
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
- Kim Reiss BinderPhiladelphia$16.9M
- Carl JunePhiladelphia$13M
- Takami SatoPhiladelphia$11.5M
- Vivek NarayanPhiladelphia$10.6M
- Ubaldo Martinez-OutschoornPhiladelphia$10.5M
- Neil PalmisianoPhiladelphia$10.1M
- Anthony OlszanskiPhiladelphia$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.